The global lung cancer therapeutics market was valued at USD 18.3 billion in 2021 and it is anticipated to grow further till USD 74.1 billion by 2031, at a CAGR of 15.0% during the forecast period.
Global Lung Cancer Therapeutics report from Global Insight Services is the single authoritative source of intelligence on Lung Cancer Therapeutics market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters’ and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market.
The uncontrolled proliferation of cells in the lung tissues causes lung cancer, a deadly lung tumor. The main risk factor for lung cancer development is cigarette smoking. Lung cancer can also be brought on by smoking tobacco for a long time. Using bronchoscopy or CT guidance, a biopsy is performed to confirm the diagnosis of lung cancer. Therefore, chemotherapy, radiation, immunotherapy, surgery, etc. can all be used to treat lung cancer.
To Remain ‘Ahead’ Of Your Competitors, Request for A Sample – https://www.globalinsightservices.com/request-sample/GIS10320
Key Players
- Genentech (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca
- Pfizer Inc.
- Sanofi
- Novartis AG
- Astellas
- Bristol Myers Squibb
Global Lung Cancer Therapeutics Market Segmentation
By Therapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
By Cancer Type
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
Get Customized Report as Per Your Requirement – https://www.globalinsightservices.com/request-customization/GIS10320
Market Trends and Drivers
Rising cancer awareness in both developed and developing countries, the introduction of new medical diagnostic tools and cutting-edge treatments, and an increase in lung cancer diagnoses have all contributed to the market expansion for lung cancer medicines. The expansion of the global market is also being boosted by this, along with rising investments made by leading players in research and development activities. Due to an increase in lung cancer cases, more attention is being paid to R&D projects, which is what is causing the market to alter.
The targeted therapy segment is anticipated to dominate the market during the forecast period. The key factors such as increasing R&D advances leading to greater adoption of sophisticated and advanced therapies such as immunotherapy coupled with the increasing prevalence of lung cancer is boosting the growth of the market.
The non-small cell lung cancer segment is anticipated to dominate the market during the forecast period. The increasing prevalence of all types of cancers are prevalent in the general population and lung cancer is one of the most common forms of cancer.
Purchase your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS10320/
With Global Insight Services, you receive:
- 10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Excel data pack included with all report purchases
- Robust and transparent research methodology
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700